Progression of mesenchymal stem cell regulation on imbalanced microenvironment after spinal cord injury

Stem Cell Research & Therapy, Journal Year: 2024, Volume and Issue: 15(1)

Published: Oct. 1, 2024

Language: Английский

---

Multiple strategies enhance the efficacy of MSCs transplantation for spinal cord injury

Biomedicine & Pharmacotherapy, Journal Year: 2022, Volume and Issue: 157, P. 114011 - 114011

Published: Nov. 18, 2022

Spinal cord injury (SCI) is a serious complication of the central nervous system (CNS) after spine injury, often resulting in severe sensory, motor, and autonomic dysfunction below level injury. To date, there no effective treatment strategy for SCI. Recently, stem cell therapy has brought hope to patients with neurological diseases. Mesenchymal cells (MSCs) are considered be most promising source cellular SCI due their immunomodulatory, neuroprotective angiogenic potential. Considering limited therapeutic effect MSCs complex pathophysiological environment following SCI, this paper not only reviews specific mechanism facilitate repair, but also further discusses research status these pluripotent combined other approaches promote anatomical functional recovery post-SCI.

Language: Английский

---

Therapeutic potential of small extracellular vesicles derived from mesenchymal stem cells for spinal cord and nerve injury

Frontiers in Cell and Developmental Biology, Journal Year: 2023, Volume and Issue: 11

Published: March 22, 2023

Neural diseases such as compressive, congenital, and traumatic injuries have diverse consequences, from benign mild sequelae to severe life-threatening conditions with associated losses of motor, sensory, autonomic functions. Several approaches been adopted control neuroinflammatory cascades. Traditionally, mesenchymal stem cells (MSCs) regarded therapeutic agents, they possess growth factors cytokines potential anti-inflammatory regenerative effects. However, several animal model studies reported conflicting outcomes, therefore, the role MSCs a source for treatment neural pathologies remains debatable. In addition, issues heterogeneity ethical limited their use agents. To overcome obstacles traditional we explored potentials extracellular vesicles (EVs), which contain nucleic acids, functional proteins, bioactive lipids, play crucial roles in immune response regulation, inflammation reduction, cell-to-cell communication. EVs may surpass size issue, immunogenicity, host environment. comprehensive review is required on pathologies. this review, discuss action mechanism EVs, treating pathologies, future perspectives regarding clinical applications.

Language: Английский

---

Human umbilical cord mesenchymal stem cell-derived exosomes combined with mouse nerve growth factor can more effectively ameliorate the motor disorder and brain pathological injury in mice with cerebral palsy

Advances in Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 34(7), P. 0 - 0

Published: Jan. 8, 2025

Background.Cerebral palsy (CP) is a neurodevelopmental disorder and motor syndrome.It has been confirmed that mesenchymal stem cells (MSCs) mouse nerve growth factor (mNGF) can repair brain tissue damage injury; however, exosomes derived from healthy may have comparable therapeutic potential as the themselves.Objectives.The purpose of this study was to explore improvement effect human umbilical cord cell (hUC-MSCs)-derived on CP model determine whether there synergistic when combined with mNGF. Materials methods.Exosomes were isolated hUC-MSCs examined using transmission electron microscopy (TEM), particle size western blot (WB).A total 38 BALB/c mice (male, postnatal day 6 (PND6)) randomly divided into 5 groups: sham group, CP-exo CP-mNGF CP-exo-mNGF group.Hypoxic induction after unilateral common carotid artery ligation lipopolysaccharide (LPS) infection used construct model.Pathological neuron synaptic structures in hippocampus light hematoxylin-eosin (H&E) staining TEM, respectively.Survival neurons evaluated Nissl staining.Western applied monitor PSD-95 synaptophysin (SYN) protein levels.Results.This indicated released by ameliorated structure destruction induced hypoxic ischemia LPS infection.When mNGF, more effective improvement.In neuronal function severely impaired; hUC-MSCs-derived mNGF improved it.PSD-95 SYN proteins presynaptic postsynaptic proteins, respectively.Interestingly, levels significantly lower mice, but addition hUC-MSCs-exosomes or they increased significantly, especially group.Conclusions.The injury be most are through intraperitoneal (ip.) administration.

Language: Английский

---

Induced pluripotent stem cell-derived mesenchymal stem cells for modeling and treating metabolic associated fatty liver disease and metabolic associated steatohepatitis: Challenges and opportunities

World Journal of Stem Cells, Journal Year: 2025, Volume and Issue: 17(2)

Published: Feb. 24, 2025

The potential of induced pluripotent stem cells (iPSCs) for modeling and treating metabolic associated fatty liver disease (MAFLD) steatohepatitis (MASH) is emerging. MAFLD a growing global health concern, currently with limited treatment options. While primary mesenchymal hold promise, iPSCs offer versatile alternative due to their ability differentiate into various cell types, including iPSC-derived cells. However, challenges remain, optimizing differentiation protocols, ensuring safety, addressing tumorigenicity risks. In addition, the possibility generate complex cellular models, three-dimensional organoid which are closer representations human than animal models. Those models would also be valuable drug discovery personalized medicine approaches. Overall, derivatives new perspectives advancing MAFLD/MASH research developing novel therapeutic strategies. Further needed overcome current limitations translate this effective clinical applications.

Language: Английский

---